Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.

ABSTRACT:

Background

Patients with relapsed or refractory (R/R) lymphomas have benefited from chimeric antigen receptor (CAR)-T-cell therapy. However, this treatment is linked to a high frequency of adverse events (AEs), such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity. There has been increasing interest in hematological toxicity in recent years, as it can result in additional complications, such as infection or hemorrhage, which remain intractable.

Methods

We conducted a retrospective, single-institution study to evaluate the patterns and outcomes of cytopenia following CAR-T-cell infusion and potential associated factors.

Results

Overall, 133 patients with R/R lymphoma who received CAR-T-cell the

SUBMITTER: Zhou J 

PROVIDER: S-EPMC9484486 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature